India has roughly 18 million children living with neurodevelopmental disorders — autism, ADHD, cerebral palsy, learning disabilities — and fewer than 10,000 trained therapists certified to support them. That treatment gap is the market Rays of Belief Limited built its Mom’s Belief network to address — and the Rays of Belief IPO is the company’s ₹125 crore capital ask to scale from 136 centres today toward the national footprint the demand requires.
The question every retail investor must answer before the September 3, 2026 close is the same one they face with every pre-profitability healthcare issue: does the social enterprise story translate into investable equity returns at ₹239 per share?
What Is Rays of Belief Limited and the Business Behind Mom’s Belief
The Rays of Belief IPO brings to Dalal Street a category India’s primary market has never had access to before — organised, multi-centre, branded neurodevelopmental disorder therapy for children.
Rays of Belief Limited, incorporated in 2017 and headquartered at Chittranjan Park, New Delhi, is a for-profit social enterprise that operates India’s largest NDD therapy centre chain under the Mom’s Belief brand (momsbelief.com). The company serves children aged 18 months to 12 years across Autism Spectrum Disorder (ASD), ADHD, Down Syndrome, Cerebral Palsy, Intellectual Disability, Learning Disabilities, and Global Developmental Delay — with vocational and life-skills programs extending to age 15.
The network spans 136 centres across 20 states and union territories, staffed by 340+ clinical professionals. Services include early intervention, occupational therapy, language therapy, parental guidance, and family support programs, supported by 150+ teaching tools at each centre and 2,000+ home learning resources.
Promoters Nitin Bindlish and Carving Futures Pte. Ltd. held 91.72% pre-IPO, reducing to 68.77% post-issue — a healthy stake retention that signals long-term conviction. The company’s US subsidiary, Moms Belief US Inc., handles international operations, with IPO proceeds earmarked for US centre lease payments.
Rays of Belief IPO Date, Price Band, and Complete Subscription Details
The Rays of Belief IPO opened for public subscription on September 1, 2026 and closed on September 3, 2026, with listing on BSE and NSE confirmed for September 8, 2026.
| Field | Details |
|---|---|
| Open / Close | September 1 – September 3, 2026 |
| Listing Date | September 8, 2026 (BSE + NSE) |
| Price Band | ₹227 – ₹239 per share |
| Face Value | ₹10 per share |
| Issue Size | ~₹125 crore (100% fresh issue) |
| OFS | Nil |
| Lot Size | 62 shares |
| Retail Minimum | ₹14,818 (1 lot, 62 shares) |
| Retail Maximum | ₹1,92,634 (13 lots, 806 shares) |
| S-HNI Minimum | ₹2,07,452 (14 lots, 868 shares) |
| B-HNI Minimum | ₹10,07,624 (68 lots) |
| Allotment Date | September 4, 2026 |
| Demat Credit / Refunds | September 7, 2026 |
| Lead Manager | Mefcom Capital Markets Ltd. |
| Registrar | KFin Technologies Ltd. |
| Promoters | Nitin Bindlish; Carving Futures Pte. Ltd. |
| Anchor Bidding Date | August 31, 2026 (₹50 crore raised) |
Investor Reservation — Retail Quota Is Only 10%:
| Category | Shares | Allocation |
|---|---|---|
| Anchor Investor | 20,92,190 | 40% of QIB portion |
| QIB (ex. Anchor) | 18,30,310 | 35% |
| NII / HNI | 7,84,500 | 15% |
| Retail (RII) | 5,23,000 | 10% |
The retail quota of 10% — the same unusual structure as the Purple Style Labs IPO in the same September 2026 mainboard batch — means only ₹12.5 crore of the ₹125 crore issue is available for Retail Individual Investors. At likely oversubscription, a 13-lot maximum application (₹1,92,634) will probably yield just one lot (₹14,818 at cost). Anchor investors locked in ₹50 crore on August 31 — the full anchor list is available on BSE.
Where Does ₹125 Crore Go? Objects of the Issue
Every rupee raised through the Rays of Belief IPO is a fresh issue — no OFS, no promoter exit, all capital stays with the company for operational and expansion purposes.
| Purpose | Amount (₹ Cr) |
|---|---|
| New Company Learning Centres | ₹26.88 |
| School Collaboration Centres | ₹5.54 |
| Centre for Excellence and Research | ₹2.45 |
| Upskilling Academy | ₹2.05 |
| Technology (hardware) costs | ₹4.44 |
| Lease payments — existing India centres | ₹14.45 |
| Subsidiary (Moms Belief US Inc.) — US lease payments | ₹10.13 |
| Brand awareness and inclusive outreach | ₹10.21 |
| Inorganic growth / General corporate purposes | Balance |
The largest single allocation — ₹26.88 crore — funds new Company Learning Centres, a direct capacity addition. However, a significant share of remaining proceeds covers operating costs: ₹14.45 crore for existing India centre leases and ₹10.21 crore for brand awareness create no tangible balance sheet assets.
The ₹10.13 crore earmarked for Moms Belief US Inc. extends the capital ask to international markets at a stage where Indian operations have not yet reached consistent post-depreciation profitability. The Upskilling Academy allocation of ₹2.05 crore directly addresses India’s structural shortage of certified child therapists — a bottleneck that threatens to slow the very centre expansion this IPO funds.
Rays of Belief IPO Financials — Revenue Up 167% in Two Years, Profit Under Scrutiny
The financial record behind the Rays of Belief IPO is one of strong revenue acceleration paired with a profit line that requires careful reading before any investment decision.
| Year | Revenue (₹ Cr) | Expenses (₹ Cr) | PAT (₹ Cr) | Assets (₹ Cr) |
|---|---|---|---|---|
| FY24 | ₹30.76 | ₹30.66 | ₹0.85 | ₹12.89 |
| FY25 | ₹36.54 | ₹36.19 | ₹5.88* | ₹26.12 |
| FY26 | ₹82.06 | ₹75.16 | ₹4.96 | ₹50.89 |
*FY25 PAT includes a ₹5.53 crore one-time deferred tax credit. Underlying operating profit in FY25 was approximately ₹0.35 crore — near breakeven on a normalised basis.
Revenue grew from ₹30.76 crore (FY24) to ₹82.06 crore (FY26), a 63.34% CAGR driven by rapid centre additions across 20 states. FY26 EBITDA margin reached 14.59%, confirming the business covers its direct operating costs — but lease amortisation, fitout depreciation, and overhead compressed PAT to ₹4.96 crore at a 6.07% margin.
The profit trend actually reversed in FY26: PAT fell from ₹5.88 crore (FY25, inflated by the one-time tax credit) to ₹4.96 crore despite revenue surging 124% in that single year. On a normalised basis, FY26 marks the first year of genuine operating profitability — FY24 delivered ₹0.85 crore and FY25’s real profit was approximately ₹0.35 crore.
EPS stands at ₹3.21 (basic), NAV at ₹15.67, and ROE at 21.64% — solid return metrics on current equity, though post-issue equity dilution will reduce EPS going forward.
Rays of Belief IPO Valuation — What ₹239 Per Share Actually Buys
The Rays of Belief IPO price of ₹239 implies a P/E of approximately 74.5x on FY26 basic EPS of ₹3.21 — placing it among the most aggressively priced mainboard issues of September 2026. P/BV stands at ~15.3x on NAV of ₹15.67; at a post-issue market cap of approximately ₹570 crore on FY26 revenue of ₹82 crore, Price/Revenue is ~6.9x.
No listed peers exist in India — the DRHP explicitly states this — removing the standard comparative P/E framework retail investors rely on for valuation anchoring.
Bull case: India has 18 million NDD-affected children with structural undersupply of certified therapists; Rays of Belief Limited is the only scaled, branded NDD therapy network accessible to public market investors, and comparable healthcare platform businesses — Dr. Agarwal’s Eye Hospital, Pristyn Care pre-IPO — raised capital at revenue multiples ahead of profit scale.
Bear case: A P/E of ~74.5x on ₹4.96 crore of actual FY26 profit, with no listed peer as a price anchor and US expansion adding complexity before the India business achieves consistent post-depreciation earnings, demands 5+ years of compounded profit growth to justify current pricing. Price discovery depends entirely on QIB conviction, not retail valuation.
How This IPO Compares to a Standard Mainboard Offering
The table below shows where the Rays of Belief IPO diverges from typical mainboard IPO norms — every deviation has a direct implication for how retail investors should size and approach this issue.
| Parameter | Rays of Belief IPO | Typical Mainboard IPO |
|---|---|---|
| Issue Size | ₹125 crore | ₹500 crore+ (median) |
| OFS Component | Nil (100% fresh) | Often 30–60% OFS |
| Retail Quota (RII) | 10% | 35% (SEBI standard) |
| QIB Quota | 75% | 50% |
| Profit Track Record | PAT ₹4.96 Cr on ₹82 Cr revenue | Usually 3 years of consistent PAT |
| P/E at Upper Band | ~74.5x | Typically 20–50x for profitable IPOs |
| Listed Peers | None | Usually disclosed |
| Lead Manager Tier | Mefcom Capital Markets (mid-tier) | Kotak, ICICI, Axis, SBI Capital, etc. |
| Business Category | Social enterprise / NDD healthcare | Diversified manufacturing/services |
| International Operations | Active (Moms Belief US Inc.) | Rare at ₹125 Cr issue scale |
The QIB-heavy allocation structure (75%) places price discovery entirely in institutional hands, not retail consensus. The Deepa Jewellers IPO, which listed in the same September 2026 batch with a standard 35% retail quota, 56% ROE, and consistent three-year PAT, offers a direct structural contrast — both in financial profile and in what retail investors can realistically expect on allotment and listing.
Rays of Belief IPO GMP Today — What ₹47 Tells Investors About September 8
The Rays of Belief IPO GMP stood at ₹47 per share at subscription close on September 3, 2026 — implying an estimated listing price of approximately ₹286 at the ₹239 upper band, a ~19.7% grey market premium.
The GMP trajectory during the subscription window showed meaningful momentum: it opened at ₹12 (~5%) on Day 1, climbed to ₹38 (~15.9%) by Day 2, and reached ₹47 by close. This compares favourably to the Purple Style Labs IPO (₹28 / 4.9%) in the same batch and signals genuine grey market interest in the children therapy care story.
GMP is informal and unregulated — SEBI does not oversee grey market activity, and these figures carry no predictive guarantee for actual listing performance. The most reliable listing signal is QIB subscription data, published in real time on NSE during the subscription window — heavy QIB oversubscription is the institutional validation that determines September 8 price behaviour, not retail demand or grey market premium alone.
Subscription Tracking and Allotment — What Retail Investors Need to Check
The Rays of Belief IPO subscription status data is published in real time on the NSE bid monitoring dashboard and the BSE IPO subscription page from September 1 onward. With only ₹12.5 crore allocated to the RII (Retail Individual Investor) category, even moderate retail participation at maximum lot sizes could produce 15–20x oversubscription.
QIB subscription — covering 75% of the issue — is the signal that matters most. Published in real time after Day 2 (September 2) on NSE and BSE, a QIB oversubscription rate above 10x confirms strong institutional conviction ahead of the September 8 listing on both exchanges.
Anchor investors who committed ₹50 crore on August 31 face a 30-day lock-in on 50% of their shares until October 4, 2026, and a 90-day lock-in on the remaining 50% until December 3, 2026 — which limits near-term institutional selling pressure in the first month post-listing.
Allotment status will be available from September 4, 2026 at the KFin Technologies registrar portal using PAN or application number. Demat credit and refunds both process on September 7.
Five Risks Specific to This IPO That Retail Investors Must Read
High P/E with no earnings consistency: At ~74.5x FY26 EPS of ₹3.21, the valuation demands sustained double-digit profit growth; FY25’s inflated PAT (₹5.53 crore one-time tax credit) and FY26’s nominal profit decline make that earnings trajectory unproven across business cycles.
No listed peers removes the institutional price anchor: Without comparable listed companies, QIBs must price this issue purely on revenue trajectory and sector conviction — a framework that historically produces wide post-listing price swings when expectations diverge from actual quarterly results.
10% retail quota limits allotment to near-symbolic levels: With only ₹12.5 crore for RII investors, a 13-lot application (₹1,92,634) at 20x oversubscription yields one lot (62 shares, ~₹14,818 at cost) — making this primarily a listing-day play rather than a meaningful portfolio position for retail investors.
US subsidiary expansion adds FX and execution risk: The ₹10.13 crore committed to Moms Belief US Inc. for US lease payments extends financial risk to a market where the company has no operating track record, before Indian profitability has reached a self-sustaining level.
Therapist supply constrains centre-level economics: India’s shortage of certified developmental paediatricians, speech therapists, and child psychologists is both the market opportunity and the binding constraint — faster centre addition than therapist training produces underutilised capacity, depressing revenue per centre and widening losses.
5 Practical Tips Before Applying to the Rays of Belief IPO 2026
Tip 1 — Complete your UPI mandate before 5 PM on September 3: For UPI ASBA applications via Zerodha, Groww, or AngelOne, the UPI block mandate must be approved before the closing cut-off — delayed approvals result in auto-rejection without recourse.
Tip 2 — Model realistic allotment, not application size: At 10% retail quota and probable heavy oversubscription, a 13-lot application (₹1,92,634 applied) will likely yield one lot (₹14,818 allotted). Build position sizing around allotted value, not application value.
Tip 3 — Watch QIB subscription on September 2 afternoon: With QIBs controlling 75% of the issue, their real-time subscription rate on Day 2 is the single most predictive data point for listing outcome — available free on NSE and BSE bid monitoring pages.
Tip 4 — Frame this as a 3–5 year thesis, not a listing trade: At ~74.5x P/E, listing gains depend entirely on institutional momentum and GMP continuation — not earnings. Long-term investors who believe India’s organised NDD therapy market will reach 500+ centres and consistent EBITDA-to-PAT conversion have a clearer risk-adjusted case than listing-day traders.
Tip 5 — Check Rays of Belief IPO allotment status from September 4 at KFin: Access the allotment outcome at ipostatus.kfintech.com using PAN or application number — refunds and demat credit both process September 7.
Frequently Asked Questions
What is the Rays of Belief IPO GMP today? The Rays of Belief IPO GMP stood at ₹47 per share at subscription close on September 3, 2026, implying an estimated listing price of approximately ₹286 — a ~19.7% premium over the ₹239 upper band. GMP is unregulated and informal; it does not guarantee the actual listing price on September 8, 2026.
What is the Rays of Belief IPO date, and when is the allotment date? The Rays of Belief IPO subscription ran September 1–3, 2026. The Rays of Belief IPO allotment date is September 4, 2026, with demat credit and refunds processing on September 7, and listing on BSE and NSE on September 8, 2026.
Should I apply — what does the Rays of Belief IPO review actually say? The Rays of Belief IPO review is cautiously positive for long-term investors: revenue grew 167% in two years, the NDD therapy market is structurally underpenetrated, and GMP reflected genuine grey market interest at ₹47. The P/E of ~74.5x, normalised PAT of ₹4.96 crore on ₹82 crore revenue, and 10% retail quota make this unsuitable for quick listing-gain strategies. A 3–5 year horizon and tolerance for early-stage healthcare risk are prerequisites. Consult a SEBI-registered financial advisor before applying.
How do I check Rays of Belief IPO subscription status? The Rays of Belief IPO subscription status data was published in real time on the NSE bid monitoring dashboard and BSE IPO subscription page from September 1. Final subscription figures — broken by QIB, NII, and Retail categories — are published on NSE and BSE after the September 3 close. Registrar KFin Technologies processes allotment on September 4.
Can retail investors meaningfully participate given the 10% quota? At 10% retail allocation, the RII category had only ₹12.5 crore available — meaning 13-lot applications of ₹1,92,634 realistically yield one lot at cost. Retail participation here is viable as a small, IPO-subscription exposure to India’s children therapy care market, not as a portfolio-level position. Proportional allotment rules apply as they do on all mainboard NSE IPO and BSE IPO issues.
136 Centres, 18 Million Children, and India’s Largest NDD Therapy Network — The Rays of Belief IPO Has Answered the Market Call; Now Retail Investors Must Decide If They Believe the Story at ₹239
The bull case for the Rays of Belief IPO is a structural scarcity argument: India’s 18 million NDD-affected children are served by fewer than 10,000 certified therapists, and Rays of Belief Limited is the only scaled, branded, multi-state therapy network now accessible to public market investors as a listed equity.
The bear case is a valuation discipline argument: ~74.5x P/E, 6.07% PAT margin, FY25 profits that were largely one-time accounting, and no listed peer for price calibration leave the September 8 listing entirely dependent on QIB conviction — not retail demand or earnings justification.
The QIB-heavy 75% allocation structure means retail investors follow the institutional decision, not the other way around. For long-term investors who believe India’s organised children’s therapy market will scale from 136 to 500+ centres and approach consistent EBITDA-to-PAT conversion over five years, this is an early-stage entry into a category with no comparables and genuine demand tailwinds. For investors who need earnings anchor, a book-value floor, or near-term listing momentum with meaningful allotment — the Rays of Belief IPO profile at ₹239 per share does not provide those conditions.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. IPO investments are subject to market risks. This site is not SEBI registered. All financial data sourced from company filings and publicly available IPO documents. Readers are advised to consult a SEBI-registered financial advisor before making any investment decisions.